Meeting
2013 ASCO Annual Meeting
The prospective MammaPrint MINT (Multi-Institutional Neo-adjuvant Therapy) study.
Authors
Charles E. Cox
USF Health, Tampa, FL
Charles E. Cox , Peter William Blumencranz , Ruben A. Saez , Robert Wesolowski , Lisette Stork , Femke De Snoo , Jessica Gibson , Nicole Howard , Eli Avisar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT01501487
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS11122)
DOI
10.1200/jco.2013.31.15_suppl.tps11122
Abstract #
TPS11122
Poster Bd #
55C
Abstract Disclosures
Similar Posters
First Author: Charles E. Cox
Poster
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
First Author: Alice P. Chung
Poster
2020 ASCO Virtual Scientific Program
HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.
First Author: John Bartlett
Poster
2013 Breast Cancer Symposium
The accuracy of preoperative U.S.-guided vacuum-assisted breast biopsy (VABB) in determining ER, PgR, HER2, and Ki67 status in early breast cancer.
First Author: Keitaro Kamei